Global Thyroid Gland Disorder Treatment Market 2017-2021

  • ID: 4143993
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 6
About Thyroid Gland Disorder Treatment

The thyroid gland plays an important role in maintaining the functions of different organs in the body such as the heart, brain, liver, kidneys, and skin. It produces T4 and T3 hormones. The thyroid-stimulating hormone (TSH) determines the quantity of the T3 and T4 hormones production in the body. The hormones are produced and stored in the microscopic follicles of the thyroid gland. The levels of thyroid hormones are maintained with a good network of communication between the hypothalamus, pituitary gland, and thyroid gland (HPT). Slight changes in the HPT axis due to any disease, damage to the thyroid, or the use of certain medicines will lead to either low or excess production of thyroid hormones, leading to hyperthyroidism and hypothyroidism.

The analysts forecast the global thyroid gland disorder treatment market to grow at a CAGR of 3.24% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global thyroid gland disorder treatment market for 2017-2021. To calculate the market size, the report considers the global demand for thyroid gland disorder treatment.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Oscilloscope Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Pfizer
- Merck Sharp & Dohme

Market drivers
- Increasing demand for levothyroxine
- For a full, detailed list, view the full report

Market challenges
- Side effects leading to lesser patient adherence
- For a full, detailed list, view the full report

Market trends
- Rising focus on emerging economies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 6
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
  • Highlights
  • Key pipeline
PART 05: Market landscape
  • Market overview
  • Five forces analysis
PART 06: Market segmentation by type
  • Hypothyroidism
  • Hyperthyroidism
PART 07: Geographical segmentation
  • Thyroid gland disorder treatment in Americas
  • Thyroid gland disorder treatment market in EMEA
  • Thyroid gland disorder treatment market in APAC
PART 08: Market drivers
  • Rising global awareness programs
  • Increasing demand for levothyroxine
  • Growing patient population with iodine deficiency
PART 09: Impact of drivers

PART 10: Market Challenges
  • High entry barrier
  • Product recall
  • Side effects leading to lesser patient adherence
PART 11: Impact of drivers and challenges

PART 12: Market trends
  • Rising focus on emerging economies
  • Increased outsourcing of non-core activities
  • Growing focus on natural drugs
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Abbott
  • AbbVie
  • Allergan
  • Merck Sharp & Dohme
  • Pfizer
  • RLC LABS
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Key pipeline products and clinical trial stage
Exhibit 02: Global thyroid disorder treatment market snapshot
Exhibit 03: Global thyroid gland disorder treatment market 2016-2021 ($ millions)
Exhibit 04: Five forces analysis
Exhibit 05: Symptoms of hypothyroidism disorder
Exhibit 06: Global hypothyroidism drug market 2016-2021 ($ millions)
Exhibit 07: Symptoms of hyperthyroidism
Exhibit 08: Treatment for hyperthyroidism
Exhibit 09: Global hyperthyroidism drug market 2016-2021 ($ millions)
Exhibit 10: Market scenario in Americas
Exhibit 11: Thyroid gland disorder market in Americas 2016-2021 ($ millions)
Exhibit 12: Market scenario in EMEA
Exhibit 13: Thyroid gland disorder treatment market in EMEA 2016-2021 ($ millions)
Exhibit 14: Market scenario in APAC
Exhibit 15: Thyroid gland disorder treatment market in APAC 2016-2021 ($ millions)
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Competitive structure analysis of global thyroid gland disorder treatment market 2016
Exhibit 19: Competitive analysis of global thyroid gland disorder treatment market 2016
Exhibit 20: Market share analysis 2015
Exhibit 21: Market penetration of various vendors 2016
Exhibit 22: Abbott: Key highlights
Exhibit 23: Abbott: Strength assessment
Exhibit 24: Abbott: Strategy assessment
Exhibit 25: Abbott: Opportunity assessment
Exhibit 26: AbbVie: Key highlights
Exhibit 27: AbbVie: Strength assessment
Exhibit 28: AbbVie: Strategy assessment
Exhibit 29: AbbVie: Opportunity assessment
Exhibit 30: AbbVie: YoY revenue and growth rate of Synthroid 2013-2015 ($ million)
Exhibit 31: Allergan: Key highlights
Exhibit 32: Allergan: Strength assessment
Exhibit 33: Allergan: Strategy assessment
Exhibit 34: Allergan: Opportunity assessment
Exhibit 35: Merck Sharp & Dohme: Key highlights
Exhibit 36: Merck Sharp & Dohme: Strength assessment
Exhibit 37: Merck Sharp & Dohme: Strategy assessment
Exhibit 38: Merck Sharp & Dohme: Opportunity assessment
Exhibit 39: Merck Sharp & Dohme: YoY revenue and growth rate of Euthyrox 2014-2015 ($ millions)
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: RLC LABS: Strength assessment
Exhibit 45: RLC LABS: Strategy assessment
Exhibit 46: RLC LABS: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
New Report Released: – Global Thyroid Gland Disorder Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global thyroid gland disorder treatment market: AbbVie, Pfizer, and Merck Sharp & Dohme

Commenting on the report, an analyst from the research team said: “Globally, the thyroid gland disorder treatment market is expected to grow at a high growth rate owing to the rising prevalence of thyroid gland disorders. The market has witnessed a growing preference for thyroid therapeutics in developed as well as developing regions. The vendors are focusing on the untapped emerging economies such as the Middle East, Africa, China, and India. According to research studies, it is estimated that 42 million people in India suffer from thyroid diseases. According to research studies, hypothyroidism is more affected in women aged 46-54 years. Therefore, many domestic and foreign vendors are looking to tap the high potential regions. For instance, companies such as AbbVie and Merck Sharp & Dohme collaborated with ITS to increase the awareness about thyroid gland disorders among individuals.”

According to the report, globally, 750 million people suffer from thyroid disorders, among which more than half are undiagnosed. The AACE has initiated a campaign to increase public awareness about thyroid disorders and educate the Americans regarding the treatment. These camps were to educate people about increased risk for developing a thyroid disorder, the prevalence of the disease, and focus on educating and preventing programs. Globally, every year, the International Thyroid Awareness Week is celebrated in the month of November.

Further, the report states that the thyroid gland disorder treatment market witnesses the presence of many large players and makes it difficult for smaller companies to come up with innovative products. This sets the high entry barrier for new players. The global thyroid gland disorder market is in an oligopoly with Abbott, AbbVie, and Merck Sharp & Dohme maintaining a dominant share of 65% in 2016. These three companies have established their presence in the market with technologically advanced devices that have a competitive advantage over other players. These companies, which have various distribution channels and contracts with leading hospitals and health centers pose a big challenge for newer and smaller companies to penetrate the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 6
  • AbbVie
  • Pfizer
  • Merck Sharp & Dohme
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll